BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 18415784)

  • 21. A prospective, double-blind, randomized, controlled trial on the efficacy and cardiorenal safety of iodixanol vs. iopromide in patients with chronic kidney disease undergoing coronary angiography with or without percutaneous coronary intervention.
    Nie B; Cheng WJ; Li YF; Cao Z; Yang Q; Zhao YX; Guo YH; Zhou YJ
    Catheter Cardiovasc Interv; 2008 Dec; 72(7):958-65. PubMed ID: 19021282
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Renal toxicity evaluation and comparison between visipaque (iodixanol) and hexabrix (ioxaglate) in patients with renal insufficiency undergoing coronary angiography: the RECOVER study: a randomized controlled trial.
    Jo SH; Youn TJ; Koo BK; Park JS; Kang HJ; Cho YS; Chung WY; Joo GW; Chae IH; Choi DJ; Oh BH; Lee MM; Park YB; Kim HS
    J Am Coll Cardiol; 2006 Sep; 48(5):924-30. PubMed ID: 16949481
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Iso-osmolality versus low-osmolality iodinated contrast medium at intravenous contrast-enhanced CT: effect on kidney function.
    Nguyen SA; Suranyi P; Ravenel JG; Randall PK; Romano PB; Strom KA; Costello P; Schoepf UJ
    Radiology; 2008 Jul; 248(1):97-105. PubMed ID: 18483232
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Effectiveness of nephroprotection by the selection of contrast media used during vascular interventions in patients with chronic renal failure?].
    Schönefeld E; Höwler S; Osada N; Torsello G
    Zentralbl Chir; 2011 Oct; 136(5):426-30. PubMed ID: 22009540
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Renal tolerability of iopromide and iodixanol in 562 renally impaired patients undergoing cardiac catheterisation: the DIRECT study.
    Chen Y; Hu S; Liu Y; Zhao R; Wang L; Fu G; He Q; Su X; Zheng Y; Qi X; Liu H; Wang J; Gao W; Wang M; Liu S; Zheng X; He B; Yang P; Zhou S; Gao C; Qiu C
    EuroIntervention; 2012 Nov; 8(7):830-8. PubMed ID: 23045301
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nephrotoxicity of low-osmolality versus iso-osmolality contrast agents: impact of N-acetylcysteine.
    Briguori C; Colombo A; Airoldi F; Morici N; Sangiorgi GM; Violante A; Focaccio A; Montorfano M; Carlino M; Condorelli G; Ricciardelli B
    Kidney Int; 2005 Nov; 68(5):2250-5. PubMed ID: 16221226
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Contrast-induced acute kidney injury (CI-AKI) following intra-arterial administration of iodinated contrast media.
    Karlsberg RP; Dohad SY; Sheng R;
    J Nephrol; 2010; 23(6):658-66. PubMed ID: 20540038
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Iodixanol versus low-osmolar contrast media for prevention of contrast induced nephropathy: meta-analysis of randomized, controlled trials.
    From AM; Al Badarin FJ; McDonald FS; Bartholmai BJ; Cha SS; Rihal CS
    Circ Cardiovasc Interv; 2010 Aug; 3(4):351-8. PubMed ID: 20647563
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of iodixanol and iohexol in renal impairment.
    Chalmers N; Jackson RW
    Br J Radiol; 1999 Jul; 72(859):701-3. PubMed ID: 10624328
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of Intravenous Administration of Contrast Media on Serum Creatinine Levels in Neonates.
    Bedoya MA; White AM; Edgar JC; Pradhan M; Raab EL; Meyer JS
    Radiology; 2017 Aug; 284(2):530-540. PubMed ID: 28387639
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cardiac Angiography in Renally Impaired Patients (CARE) study: a randomized double-blind trial of contrast-induced nephropathy in patients with chronic kidney disease.
    Solomon RJ; Natarajan MK; Doucet S; Sharma SK; Staniloae CS; Katholi RE; Gelormini JL; Labinaz M; Moreyra AE;
    Circulation; 2007 Jun; 115(25):3189-96. PubMed ID: 17562951
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Risk of contrast-medium-induced nephropathy in high-risk patients undergoing MDCT--a pooled analysis of two randomized trials.
    Thomsen HS; Morcos SK
    Eur Radiol; 2009 Apr; 19(4):891-7. PubMed ID: 19002467
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Contrast-induced nephropathy in patients with diabetes mellitus between iso- and low-osmolar contrast media: A meta-analysis of full-text prospective, randomized controlled trials.
    Han XF; Zhang XX; Liu KM; Tan H; Zhang Q
    PLoS One; 2018; 13(3):e0194330. PubMed ID: 29558481
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nephrotoxicity of iodixanol versus ioversol in patients with chronic kidney disease: the Visipaque Angiography/Interventions with Laboratory Outcomes in Renal Insufficiency (VALOR) Trial.
    Rudnick MR; Davidson C; Laskey W; Stafford JL; Sherwin PF;
    Am Heart J; 2008 Oct; 156(4):776-82. PubMed ID: 18946896
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of the nephrotoxicity of iodixanol in patients with predisposing factors to contrast medium induced nephropathy referred for contrast enhanced computed tomography.
    Sandstede JJ; Roth A; Machann W; Kaupert C; Hahn D
    Eur J Radiol; 2007 Jul; 63(1):120-3. PubMed ID: 17317065
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Angiography with nonionic X-ray contrast media in severe chronic renal failure: renal function and contrast retention.
    Jakobsen JA; Berg KJ; Kjaersgaard P; Kolmannskog F; Nordal KP; Nossen JO; Rootwelt K
    Nephron; 1996; 73(4):549-56. PubMed ID: 8856250
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Iodixanol versus iopromide in patients with renal insufficiency undergoing coronary angiography with or without PCI.
    Zhang J; Jiang Y; Rui Q; Chen M; Zhang N; Yang H; Zhou Y
    Medicine (Baltimore); 2018 May; 97(18):e0617. PubMed ID: 29718868
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adverse events with universal use of iodixanol for CT: comparison with iohexol.
    Ho AL; O'Malley ME; Tomlinson GA
    J Comput Assist Tomogr; 2007; 31(2):165-8. PubMed ID: 17414747
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intravenous contrast material exposure is not an independent risk factor for dialysis or mortality.
    McDonald RJ; McDonald JS; Carter RE; Hartman RP; Katzberg RW; Kallmes DF; Williamson EE
    Radiology; 2014 Dec; 273(3):714-25. PubMed ID: 25203000
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Exposure to low- vs iso-osmolar contrast agents reduces NADPH-dependent reactive oxygen species generation in a cellular model of renal injury.
    Netti GS; Prattichizzo C; Montemurno E; Simone S; Cafiero C; Rascio F; Stallone G; Ranieri E; Grandaliano G; Gesualdo L
    Free Radic Biol Med; 2014 Mar; 68():35-42. PubMed ID: 24300339
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.